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Background: The combination of boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of
patients infected with HCV genotype 1 has led to significantly increased rates of sustained virological response
(SVR) in phase III trials. There is only limited data regarding the safety and efficacy in a “real-life” cohort.
Methods: We analyzed a cohort of 110 unselected HCV patients who started triple therapy from September 2011
to February 2013 by chart review with focus on the individual course of treatment, complications and outcome. We
excluded 8 patients from analysis because of HIV-coinfection (N = 6) or status post liver transplant (N = 2). Importantly,
41 patients displayed F3 or F4 fibrosis, 10 patients had a history of treatment with protease/polymerase inhibitors and
15 patients were prior partial- or null-responder.
Results: SVR12 was achieved in 62 of the 102 patients (60.8%). A high rate of serious adverse events (N = 30) was
observed in 22 patients including 2 fatalities in cirrhotic diabetes patients. Age >50 years, liver cirrhosis, bilirubin >1.1 mg/
dl (P < 0.01, each), platelets <100,000/μl (P = 0.01), ASAT >100 U/l (P = 0.03) and albumin ≤35 g/l (P = 0.04) at baseline
were associated with occurence of a SAE.
Conclusions: The frequency of SVR in a “real-life” treatment setting is slightly lower as compared to the results of the
phase III trials for telaprevir or boceprevir. Importantly, we observed a high frequency of SAE in triple therapy, especially in
patients with liver cirrhosis.
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An estimated 170 million people are chronically infected
with the hepatitis C virus (HCV) [1] and have an elevated
risk for liver-related mortality [2]. Recently, introduction
of the serine protease inhibitors (PI) boceprevir (BOC) and
telaprevir (TPR) which are used in combination with
peginterferon-alfa 2a or 2b (pegIFN) and ribavirin (RBV)
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article, unless otherwise stated.genotype 1 infection in the US, Canada and many
European countries in phase III trials with sustained
virological response (SVR) rates of 67 to 75% in treatment
naive patients [3-5]. Even higher SVR rates have been
achieved in patients with history of relapse following a
previous therapy [6,7]. Interestingly, first “real-life” efficacy
data revealed a significantly lower frequency of SVR [8].
On the other hand, treatment with a PI is associated with
high rates of side-effects, such as fatigue, anemia and high-
grade neutropenia [3-7]. Skin reactions and gastrointes-
tinal disorders were frequently observed side-effects of
TPR in the phase II and III trials [4,5,7].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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acceptable in phase III trials [3-7], which included highly
selected patients. Most recently, preliminary “real-life”
data covering the first 12 to 16 weeks of therapy
revealed considerably increased risk for severe and in
some instances even lethal complications of PI-based
treatment in cirrhotic patients [9,10]. The most common
cause of death was sepsis, with staphylococcus being the
most frequent causative organism [10].
Despite the approval of alternative direct acting antivi-
rals (DAA) in Northern America and Europe, TPR and
BOC have just arrived in many parts of the world. Given
the increased likelihood of serious adverse events (SAE)
provided by the preliminary reports on “real-life” data
[9,10], we examined the outcomes and complications of
triple therapy throughout the treatment course within our
local “real-life”, difficult-to-treat cohort, which includes
a number of patients with comorbidities, cirrhosis or pre-
vious DAA experience.
Methods
Study population and chart review
We analyzed clinical and laboratory data of 110 unselected
patients who were chronically infected with HCV genotype
1 and in whom treatment with pegIFN, RBV and TPR or
BOC was initiated from September 2011 to February 2013
at the viral hepatitis clinics of the University Medical
Center Hamburg-Eppendorf, which is representative of a
tertiary care referral center for antiviral HCV therapy in
Germany. Liver transplant recipients (N = 2) and patients
coinfected with human immunodeficiency virus were
excluded (N = 6).
All patients received an abdominal ultrasound prior to
the start of therapy. The grade of liver fibrosis was mea-
sured in the majority of patients by transient elastogra-
phy (Fibroscan, Echosens, France) [11] or liver biopsy
before the initiation of treatment (Table 1).
Patient charts were analyzed regarding demographics,
clinical data, HCV genotype, interleukin 28B (IL28B)
rs12979860 polymorphism, as well as laboratory values
and HCV viral load at different time points. The lower
detection limit of the HCV PCR was 15 IU/ml (COBAS
TaqMan HCV Qualitative, v2.0, Roche). The Child-Pugh
score and the MELD score were assessed in all cirrhotic
patients at baseline using the established formula
[12,13].
Statistical analysis
Variables of patients with SVR12 were compared with
those of patients experiencing a treatment failure by uni-
variate analysis using Fisher’s exact text, t-test (for vari-
ables with assumed Gaussian’ distribution, e.g. age) and
Mann–Whitney-U-Test (for variables without assumed
Gaussian’ distribution, e.g. laboratory values), respectively.The same analysis was conducted for patients suffering
from predefined SAEs. Thresholds for continuous vari-
ables were defined according to the results from the
CUPIC cohort [10] or by clinical judgement. Variables
which reached P < 0.1 in univariate analysis were entered
in a backward step logistic regression model.
The respective grading of laboratory events, adverse
event definitions and virological definitions are de-
scribed in the supplementary materials (text document,
Additional file 1). All analyses were performed using
SPSS Version 20. The figures were created using
GraphPad Prism 4. The study was approved at the local
ethics board (Ethik-Kommission der Ärztekammer
Hamburg).
Results
Characterization of the study population
We describe here the detailed clinical course and treatment
outcome of 102 patients who started triple therapy from
September 2011 to February 2013 at our university viral
hepatitis clinics. Baseline characteristics of all patients are
summarized in Table 1. Fibroscan or liver biopsy was
performed in 92 patients (90.2%) and diagnosis of bridging
fibrosis (F3) or cirrhosis (F4) was established in 41 patients
(40.2%). The 10 remaining patients, who did not receive a
transient elastography or a liver biopsy prior to the HCV
therapy, did not have any laboratory or sonographical
evidence for high grade fibrosis or cirrhosis, respectively.
IL28B polymorphism was assessed in 70 patients (68.6%),
of whom 16 individuals displayed the favorable C/C IL28
haplotype (22.9%). Fifty five patients (53.9%) were HCV
treatment experienced (25 patients with a prior relapse, 15
patients with prior partial- or null-response), including 10
patients who previously received a DAA based therapy in
clinical trials. The exclusion criteria for registration trials
for TPR or BOC [3-7] were met by 65 patients (64%, e.g.
history of hepatocellular carcinoma, history of stem cell
transplantation, renal dialysis, Crohn’s disease, thalassaemia
major, autoimmune hepatitis and primary biliary cirrhosis).
Twenty patients (19.6%) suffered from concomittant
psychiatric disorders such as major depression (N = 18),
anxiety disorder (N = 2), borderline psychosis (N = 1), post
traumatic stress disorder (N = 1) and anorexia (N = 1) and
were treated with psychotropics. Additionally, 10 patients
were DAA experienced as participants of several phase II
and III trials performed at our center.
In 15 patients virologic failure occured during PI treat-
ment (Figure 1). The PI was discontinued early in 25 of
the remaining 87 patients (28.7%) for various reasons (e.g.
patient’s wish, side-effects, provider’s individual decision;
Figure 2). After PI withdrawal, 5 additional patients expe-
rienced a viral breakthrough on dual therapy (Figure 1)
and 24 of the remaining 82 patients (29.3%) discontinued
pegIFN and RBV prematurely as compared to the
Table 1 Baseline characteristics
All patients Telaprevir Boceprevir
(N = 102) (N = 65) (N = 37)
N (%); median (range) N (%); median (range) N (%); median (range)
Male sex 63 (62%) 43 (66%) 20 (54%)
Exclusion criteria for appropriate phase III trials 65 (64%) 42 (65%) 23 (62%)
Treatment naïve 47 (46%) 23 (35%) 24 (65%)
Treatment experienced 55 (54%) 42 (65%) 13 (35%)
Relapse 25 (25%) 18 (28%) 7 (19%)
Null/partial response 15 (15%) 13 (20%) 2 (5%)
Breakthrough 6 (6%) 5 (8%) 1 (3%)
Discontinuation§ 5 (5%) 3 (5%) 2 (5%)
Unknown outcome 4 (4%) 3 (5%) 1 (3%)
DAA experienced 10 (10%) 9 (14%) 1 (3%)
RVR 38 (37%) 21 (32%) 17 (46%)
Genotype
Genotype 1a 39 (38%) 20 (31%) 19 (51%)
Genotype 1b 53 (52%) 37 (57%) 16 (43%)
No subtype provided 9 (9%) 7 (11%) 2 (5%)
Unknown 1 (1%) 1 (2%) 0
IL28B (N = 70)
C/C 16 (24%) 10 (20%) 6 (29%)
C/T 42 (60%) 32 (65%) 10 (48%)
T/T 12 (17%) 7 (14%) 5 (24%)
Stage of fibrosis (N = 92)
No or mild fibrosis (F0-F2) 51 (55%) 32 (49%) 19 (59%)
Bridging fibrosis (F3) 12 (13%) 6 (10%) 6 (19%)
Liver cirrhosis 29 (32%) 22 (37%) 7 (22%)
Hemoglobin [g/dl] 14.7 (10.3-18.8) 14.7 (11.1-18.8) 14.6 (10.3-17.6)
Leukocytes [x10^9/l] 6.1 (2.7-13.1) 5.9 (2.7-13.1) 6.3 (3.9-12.4)
Platelets [x10^9/l] 188 (48–377) 180 (48–377) 203 (67–338)
ASAT [U/l] 50.5 (16–328) 52 (16–328) 44 (19–156)
ALAT [U/l] 75.5 (16–271) 87 (16–271) 72 (19–227)
γGT [U/l] 66.5 (25–1274) 67 (25–1274) 62 (25–217)
Bilirubin [mg/dl] 0.5 (0.2-2.2) 0.6 (0.3-2.2) 0.5 (0.2-1.4)
Albumin [g/l] 40 (25–50) 40 (25–47) 39 (30–50)
Prothrombin time [INR] 1.00 (0.90-3.29) 1.02 (0.90-3.29) 1.00 (0.92-2.33)
Creatinine [mg/dl] 0.8 (0.5-5.8) 0.8 (0.5-1.1) 0.8 (0.5-5.8)
Viral load undetectable at
EOT 82 (80%) 51 (78%) 31 (84%)
SVR12 62 (61%) 40 (62%) 22 (59%)
[N = number; DAA = direct acting antivirals; RVR = rapid virological response; IL28B = interleukin-28B polymorphism; EOT = end of treatment; SVR12 = sustained
virological response 12 weeks after last ribavirin dose; § = cessation of prior therapy due to side-effects].
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patients treated with TPR (26.2%) and all patients treated
with BOC received a lead-in phase with pegIFN and RBV
prior to triple therapy (mean duration 4.7 weeks (TPR,standard deviation (SD) = 1.2) and 5.3 weeks (BOC, SD =
5.2), Figure 2). The rationale for starting therapy with a
lead-in phase in TPR patients was to avoid the administra-
tion of a PI after a possible RVR under pegIFN/RBV [14].
Figure 1 Efficacy of triple therapy. SVR rates for different subgroups are displayed in A and B, a characterization of treatment failures for the
total study population [C] and for BOC versus TPR [D] are given, too. Patients who died after discontinuation of therapy (N = 3) and patients who
were lost to follow up (N = 8) were not regarded as being at risk for relapse in C and D. [SVR = sustained virological response; BOC = boceprevir;
TPR = telaprevir; IL28B = interleukin 28B polymorphism; BT = breakthrough; PI = protease inhibitor].
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follow-up and are therefore regarded as treatment fail-
ures in this analysis.
Efficacy of triple therapy
Overall, 62 patients (60.8%) were successfully treated
and achieved a SVR12. As expected, prior relapsers
displayed the highest SVR rate of 72% and prior partial-
or null-responders were less likely to achieve SVR12
(46.7%). SVR12 was achieved by 57.4% of treatment
naive patients (including cirrhotics) and by 51.2% of pa-
tients with bridging fibrosis or liver cirrhosis (Figure 1).
Finally, SVR 12 was achieved by 5/10 DAA experiencedpatients (see figure in Additional file 2, which includes
an overview of the treatment regimen and clinical or
virological outcome of the trial and the course of ther-
apy with TPR or BOC for each DAA experienced
patient, as well as the course of therapy of patients with
special comorbidities. Further information on the
clinical history of the DAA experienced patients are
shown in the Additional file 1).
The HCV subtype was not significantly associated with
SVR12 in our study. However, patients infected with
HCV genotype 1a displayed an odds ratio (OR) of 0.4 to
achieve SVR12 (95% confidence interval (95%CI) 0.2-1.0,
P = 0.06), while patients with HCV genotype 1b
Figure 2 Individualized courses of treatment in our “real-life” cohort. Patients are grouped according to the respective guidelines [14,15].
Each symbol represents one patient. Patients with partial response or breakthrough under BOC/TPR are not depicted in A and B, patients with
partial response or breakthrough at any time are not depicted in C and D. All BOC patients and TPR patients who received a dual lead-in phase
prior to BOC/TPR are included in E. [BOC = boceprevir; TPR = telaprevir; PR = pegylated interferon and ribavirin; SVR = sustained virological response;
EOT = patient concluded therapy, but is short of 12 weeks after last ribavirin dose].
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5.0; P = 0.07; see table in Additional file 3). Further ana-
lysis of our small cohort revealed that neither the grade
of fibrosis, nor the IL28B haplotype, treatment experi-
ence, diabetes mellitus type 2, psychiatric disorders, the
occurence of a RVR or a reduction of the pegIFN or
RBV dose were associated with SVR12 in the univariate
analysis (see table in Additional file 3). No independent
predictors for SVR12 were identified in the multivariate
analysis.We also examined the frequency and possible conse-
quences of a shortening of the duration of PI medication
from the recommended length [15,16]. This analysis re-
vealed that a higher number of patients on BOC treatment
(17/37, 45.9%, mean duration of shortening 3.8 weeks, SD =
8.1) compared to patients on TPR treatment (9/65, 13.8%,
mean duration of shortening 0.7 weeks, SD= 2.0, P < 0.01)
reduced the time of protease therapy. The mean shortening
of TPR duration was 0.8 weeks (SD= 2.2) in patients with
later SVR12 and 0.9 weeks (SD= 2.1) in patients who later
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Figure 2B). Patients who experienced virological failure
after BOC discontinuation, displayed a mean reduction
of BOC medication time of 5.4 weeks (SD = 10.0), com-
pared to 4.0 weeks (SD = 8.1) in BOC patients who
achieved SVR12 (P = 0.68, Figure 2A). Patients who ex-
perienced a relapse discontinued pegIFN and RBV
6.5 weeks prematurely (SD = 13.4) compared to patients
who achieved SVR12 (0.4 weeks (SD = 10.7), P = 0.03,
Figure 2C and D). An early termination of pegIFN/RBV
frequently led to treatment failures in patients who
qualified for shorter treatment duration (24 weeks for
TPR or 28 weeks for BOC, respectively), as well as in pa-
tients who were at need for 48 weeks of therapy (Figure 2C
and D). Due to the small number of patients in each
group, we did not perform a subgroup analysis. The dur-
ation of the lead-in phase had no statistically significantTable 2 Side effects and serious adverse events in patients re
Number BOC
(N = 102) (N = 3
Grade 3/4 anemia 13 (12.7%)§ 4 (10.8
Grade 3/4 neutropenia 25 (24.5%) 12 (32.4
Grade 3/4 thrombopenia 14 (13.7%) 3 (8.1%
Flu-like symptoms 44 (43.1%) 20 (54.1
GI disorders 43 (42.2%) 16 (43.2
Grade 1/2 rash 35 (34.3%) 11 (29.7
Psychiatric disorder 29 (28.4%)§§ 11 (29.7
Fatigue 27 (26.5%) 15 (40.5
Anorectal dyscomfort 25 (24.5%) 1 (2.7%
Insomnia 23 (22.5%) 7 (18.9
Bronchopulmonal symptoms 20 (19.6%) 9 (24.3
Dysgeusia 10 (9.8%) 9 (24.3
Immunothyreoiditis 4 (3.9%) 0
Serious adverse event Number
Grade 4 anemia 2 Both patients rec
Grade 4 neutropenia 3 1 patient with n
Grade 4 thrombopenia 6 1 patient receive
Grade 3 rash 4 TPR was discont
DRESS/SJS None -
Neurological symptoms 2 Radial nerve par
Localized infections 3 All fully recovere
Sepsis 4 2 patients recove
Hepatic decompensation 2 Both recovered,
Decompensation of autoimmune disorder 1 First manifestatio
Ileus 2 Fully recovered a
Cardiac complications 1 Unstable angina
30 SAE occured in 22 individuals. [BOC = boceprevir; TPR = telaprevir; N = number; G
symptoms; SJS = Stevens Johnson syndrome; PTCA = percutaneous coronary angiog
psychiatric illness; §§§ = hemorrhagic proctitis in 5 patients].impact on the treatment outcome, neither in patients
treated with TPR (P = 0.30), nor in patients receiving BOC
(P = 0.68, Figure 2E).
Side-effects and complications of triple therapy
Detailed information about all side-effects are shown in
Table 2. Severe flu-like symptoms were reported by 44
patients (43.1%) and 43 patients (42.2%) showed gastro-
intestinal symptoms. Patients receiving BOC suffered
more often from dysgeusia (24.3%) and fatigue (40.5%)
than patients receiving TPR (1.5% and 18.5%, P < 0.01
and P = 0.02), while TPR based treatment was associated
with a high risk for anorectal dyscomfort (36.9% (TPR)
versus 2.7% (BOC), P < 0.01).
Thirty serious adverse events (SAE) occured in 22/102
patients (21.6%). Details on the nature and outcome of
the SAE are shown in Table 2.ceiving triple therapy
TPR P-Value
7) (N = 65)
%) 9 (13.8%) 0.77
%) 13 (20%) 0.23
) 11 (16.9%) 0.25
%) 24 (36.9%) 0.10
%) 27 (41.5%) 1
%) 24 (36.9%) 0.52
%) 18 (27.7%) 1
%) 12 (18.5%) 0.02
) 24 (36.9%)§§§ <0.01
%) 16 (24.6%) 0.63
%) 11 (16.9%) 0.44




eutropenic sepsis; all 3 recovered after dose reduction of peginterferon
d a platelet concentrate
inued early in 1 patient
esis (recovery after physiotherapy) and urine incontinency (ongoing)
d (balanitis, epididymitis, perspiratory gland abscess)
red; 2 patients died
but 1 patient died 6 weeks after discontinuation of treatment
n of autoimmune diabetes mellitus.
fter surgical intervention (1x) or conservative treatment (1x)
pectoris, full recovery after PTCA with stent implantation
I = gastrointestinal; DRESS = drug induced rash and eosinophilia with systemic
raphy; § = 5 patients received transfusion; §§ = 9 patients with history of
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(mortality 1.9%). Both suffered from cirrhosis (baseline
Child-Pugh score: 5 and 7; baseline MELD score: 7 and
12) and the patients received TPR after a four week
lead-in phase with pegIFN and RBV. More notable, both
patients had known diabetes mellitus type 2 with a base-
line HbA1c of 7.1 and 7.8%. The patient with the Child-
Pugh score of 7 had also a serum albumin < 35 g/l and a
thrombocytopenia < 100,000/µl.
In the univariate analysis advanced age (P = 0.02) and
existence of liver cirrhosis (P < 0.01) were both associated
with incidence of a predefined SAE. Furthermore, low
platelet count and high INR (P < 0.01, each), as well as
high ASAT and bilirubin (P = 0.04 and 0.01, respectively)
were associated with risk for an episode of a SAE.Table 3 Risk factors for occurence of serious adverse events i




Male sex 50 (62.5%)
Age [years] 46.7 (±12.4)
Age > 50 years 32 (40%)
Liver cirrhosis 17 (23.9%)
Diabetes mellitus type 2 8 (10%)
Psychiatric disorders 16 (20%)





Hemoglobin [g/dl] 14.7 (10.3-18
Leukocytes [x10^9/l] 6.2 (3.1-13.1
Platelets [x10^9/l] 199.5 (85–37
ASAT [U/l] 49.5 (16–156
ALAT [U/l] 70 (16–255
γGT [U/l] 62.5 (57–127
Bilirubin [mg/dl] 0.5 (0.2-1.5)
Albumin [g/l] 40 (29–50)
Prothrombin time [INR] 1.00 (0.9-3.3
Creatinine [mg/dl] 0.8 (0.5-5.8)
Platelets < 100,000/μl 5 (6.3%)
ASAT > 100 U/l 11 (13.8%)
Bilirubin≥ 1.2 mg/dl 2 (2.5%)
Albumin≤ 35 g/l 3 (3.8%)
Prothrombin time [INR] > 1.2 4 (5.3%)
[SAE = serious adverse event; N = number; SD = standard deviation; ASAT = aspartate
glutamyltransferase; INR = international normalized ratio].Age above 50 years (P < 0.01), thrombocytes < 100,000/
μl (P = 0.01), serum albumin < 35 g/l (P = 0.04), ASAT >
100 U/l (P = 0.03) and bilirubin ≥ 1.2 mg/dl (P < 0.01)
were significantly associated with the occurence of a
SAE (Table 3). Bilirubin ≥ 1.2 mg/dl (OR 13.1; 95%CI
2.1-81.4; P < 0.01) and ASAT > 100 U/l (OR 4.6; 95%CI
1.4-15.1; P = 0.01) were independent predictors for a
SAE in the multivariate analysis.
The frequency of SAE in patients with liver cirrhosis
was 41.4% (12/29). In the subgroup analysis of patients
with liver cirrhosis, median MELD score of patients with a
SAE was higher as compared to patients without compli-
cations (9 versus 7; P < 0.01). Low thrombocytes and ele-
vated INR (P < 0.01 and 0.01, respectively) were associated
with a SAE, too (see Table in Additional file 4, whichn patients receiving triple therapy















.8) 14.6 (12.3-18.0) 0.69
) 5.9 (2.7-9.5) 0.79
7) 127 (48–329) <0.01
) 67.5 (26–328) 0.04
) 91 (22–271) 0.28
4) 72 (25–459) 0.18
0.75 (0.2-2.2) 0.01
39 (25–44) 0.11







aminotransferase; ALAT = alanine aminotransferase; γGT = gamma-
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The multivariate analysis did not identify any inde-
pendent predictors for a SAE in the subgroup of cir-
rhotic patients.
Discussion
Our study aimed to extend the data obtained by the
registration trials of TPR and BOC and to describe our
“real-life” experiences of triple therapy in a large cohort
of more than 100 patients including “difficult-to-treat”
patients (including patients suffering from autoimmune
disorders, as well as patients with a major depression) as
well as a great number of patients with advanced liver
disease. The frequency of F3 or F4 fibrosis (40.2%) was
substantially higher as compared to the frequency of
bridging fibrosis or cirrhosis in the participants of the
registration trials (F3/F4 in 10 to 28% of patients) [3-7].
Of note, almost two-thirds of our patients would have
been ineligible for the various registration trials of TPR
or BOC [3-7], 15 patients (14.7%) had a history of
partial- or null-response in previous treatment and 10
patients were DAA experienced. Astonishingly, these
patients displayed a reasonable chance for SVR and the
frequency of SVR12 (60.8%) in our “real-life” cohort was
only slightly lower as compared to the results from the
registration trials [3-7], but still higher than previous
“real-life” data on dual treatment with pegIFN/RBV by
us and others [17].
At the same time – and in concordance with previous
reports [9,10] – we saw a high incidence of SAEs especially
in patients with liver cirrhosis and even two fatal outcomes
in our cohort. Counterintuitively, patients with psychiatric
disorders displayed neither a higher rate of treatment fail-
ures, nor a higher risk for the incidence of SAE.
The frequency of treatment failure at week 12 of PI
administration was reported to be as high as 29% in pre-
vious “real-life” reports [9]. Interestingly, in our cohort
only 14.7% of patients experienced a treatment failure
until week 12 of PI (13 patients with partial response
and 2 patients stopping therapy due to moderate side-
effects, Figures 1 and 2). Furthermore, the frequency of
SVR was higher as compared to the SVR rate in a most
recently published “real-life” cohort [8]. However, our
observations might (at least partly) be explained by a
higher rate of patients with bridging fibrosis or cirrhosis
in these studies, as compared to our cohort [8,9]. On the
one hand, the reduction of the pegIFN or RBV dose due
to side-effects, as well as an early PI withdrawal (when
appropriate) were not associated with lower chances for
SVR in our small cohort. On the other hand, an early
termination of pegIFN and RBV was determined by us as
a risk factor for later relapse. Future prospective studies
have to determine whether treatment individualization
and de-escalation are indeed a valid option in difficult-to-treat patients to manage side-effects and to achieve a rea-
sonable chance for SVR as seen in this retrospective study.
Our data also indicate, that triple therapy may be a
reasonable option for certain DAA-experienced patients,
too (Additional file 2). This is an important finding,
since the number of DAA-experienced patients will rap-
idly increase in the future. However, in the future testing
of protease inhibitor escape mutations before initiation
of re-treatment might be useful in these cases.
Whilst IL28B polymorphism is the strongest pretreat-
ment predictor for SVR in pegIFN/RBV based treatment
[18], our results confirm previous reports of limited
practical value of IL28B polymorphism for prediction of
SVR in patients treated with BOC or TPR [19,20].
Elevated ASAT and bilirubin at baseline were the only
independent predictors of SAE in our cohort. However,
thrombocytopenia and low serum albumin, which have
been identified as the key risk factors for hepatic decom-
pensation and death under triple therapy before [10],
were also associated with occurence of a SAE in the uni-
variate analysis in our cohort. Since all deceased patients
had cirrhosis and diabetes mellitus type 2, cirrhotic pa-
tients with diabetes should be treated with special care
since they are most likely to experience severe complica-
tions. Furthermore, we recommend that patients who
display risk factors for complications, should be referred
to an experienced viral hepatitis center.
As a consequence of the treatment complexity of triple
therapy with an increased risk for relevant and potentially
lethal side-effects, we significantly remodelled procedures
at our clinics. Every patient is discussed in a multidiscip-
linary hepatitis board before HCV triple therapy is initi-
ated. Additionally, every cirrhotic patient is seen by the
transplant team before treatment initiation and listed for
liver transplantation if deemed necessary.
Our retrospective study has certain limitations. First, in
a minority of less than 10% of patients liver cirrhosis was
not formally excluded, although none of the patients had
any clinical or laboratory signs of liver cirrhosis. Second,
we only recorded the fact of RBV dose reduction rather
than the individual RBV dose. Since we are associated with
a viral hepatitis study center, 81 additional patients (many
of them treatment naive) recruited to clinical phase II or
III trials during the study period. Finally, our cohort in-
cluded patients who were previously treated with DAA.
Although 50% of the DAA experienced patients achieved
SVR12, our study was too small to identify patients who
should receive TPR or BOC-based treatment after a viro-
logical failure in a DAA based therapy and no assessment
of protease excape mutations was performed. However, we
believe that this study reflects the “real-life” situation in
many large tertiary referral centers and our study provides
important learning points in these “challenging-to-treat”
patients for other HCV therapy providers worldwide.
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In conclusion, triple therapy with first generation PI pro-
vides a reasonable chance for SVR even in “difficult-to-
treat” patients, as presented here. However, considering
high rates of complications as reported from us and others
[9,10], careful patient selection, extensive patient educa-
tion and precise monitoring are essential, especially in pa-
tients with liver cirrhosis.
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